Page 265 - The Vasculitides, Volume 1: General Considerations and Systemic Vasculitis

Cryoglobulinemic Vasculitis 239

[4] Ferri C, Sebastiani M, Saadoun D, et al. Cryoglobulinemia and hepatitis C virus. In,
JWJ Bijsma, ed. EULAR compendium on rheumatic diseases, 2012. Chapter 42;
London: BMJ Publishing Group Ltd, 2012; pp 1042-1071.

[5] Monti G, Galli M, Invernizzi F, et al. and GISC. Italian Group for the Study of
Cryoglobulinaemias. Cryoglobulinaemias: a multi-centre study of the early clinical and
laboratory manifestations of primary and secondary disease. QJM 1995; 88: 115-126.

[6] Dammacco F, Sansonno D, Piccoli C, et al. The lymphoid system in hepatitis C virus
infection: autoimmunity, mixed cryoglobulinemia, and Overt B-cell malignancy. Semin.
Liver. Dis. 2000; 20: 143-157.

[7] Ferri C, Greco F, Longombardo G, et al. Association between hepatitis C virus and
mixed cryoglobulinemia. Clin. Exp. Rheum. 1991; 9: 621-624.

[8] Lunel F, Musset L, Cacoub P, et al. Cryoglobulinemia in chronic liver diseases: role of
hepatitis C virus and liver damage. Gastroenterology 1994; 106: 1291-1300.

[9] Ferri C, Sebastiani M, Giuggioli D, et al. Mixed cryoglobulinemia: demographic,
clinical, and serological features, and survival in 231 patients. Sem. Arthritis. Rheum.
2004; 33: 355-474.

[10] Pascual M, Perrin L, Giostra E, et al. Hepatitis C virus in patients with
Cryoglobulinemia type II. J. Inf. Dis. 1990; 162: 569-570.

[11] Ferri C, Marzo E, Longombardo G, et al. Alpha-interferon in the treatment of mixed
cryoglobulinemia patients. International Cancer Update. Focus on Interferon Alfa 2b.
Cannes, France. November 1-4, 1990. Proc. Eur. J. Cancer 1991, 27: 81-82.

[12] Ferri C, Antonelli A, Mascia MT, et al. HCV-related autoimmune and neoplastic
disorders: the HCV syndrome. Dig Liver Dis 2007; 39 (Suppl 1): S13-S21.

[13] Zignego AL, Ferri C, Giannelli F, et al. Prevalence of BCL-2 rearrangement in hepatitis
C virus-related mixed cryoglobulinemia with or without complicating B-cell
lymphoma. Ann. Int. Med. 2002; 137: 571–580.

[14] Antonelli A, Ferri C, Ferrari SM, et al . Immunopathogenesis of HCV-related endocrine
manifestations in chronic hepatitis and mixed cryoglobulinemia. Autoimmun. Rev.
2008; 8: 18-23.

[15] De Vita S, Soldano F, Isola M, et al. Preliminary classification criteria for the
cryoglobulinaemic vasculitis. Ann. Rheum. Dis. 2011; 70: 1183-1190.

[16] Ferri C, Sebastiani M, Antonelli A, et al. Current treatment of hepatitis C-associated
rheumatic diseases. Arthritis. Res. Ther. 2012; 14:215. doi: 10.1186/ar3865.

[17] Pietrogrande M, De Vita S, Zignego AL, et al. Recommendations for the management
of mixed cryoglobulinemia syndrome in hepatitis C virus-infected patients. Autoimmun.
Rev. 2011; 10: 444-454.

[18] Quartuccio L, Isola M, Corazza L, et al. Performance of the preliminary classification
criteria for cryoglobulinaemic vasculitis and clinical manifestations in hepatitis C virus-
unrelated cryoglobulinaemic vasculitis. Clin. Exp. Rheumatol. 2012; 30(Suppl 70):S48-
S52.

[19] Ferri C, Cacoub P, Mazzaro C, et al. Treatment with rituximab in patients with mixed
cryoglobulinemia syndrome: Results of multicenter cohort study and review of the
literature. Autoimmun. Rev. 2011; 11: 48-55.

Complimentary Contributor Copy